# ðŸ”® Oracle â€” Strategic Memory

## The Target

- **$11M ARR** â€” This is the number. Everything flows from this.
- Requires ~**32 customers** at ~**$344K ACV** average
- Timeline: 12-18 months from launch

## The 3-Step Plan

1. **Skills** â€” Build and prove AI agent capabilities (current phase)
2. **Service Accounts** â€” Package skills into managed service offerings for enterprises
3. **AaaS (Agents-as-a-Service)** â€” Platform play. Recurring revenue. The real business.

Each step builds the moat for the next.

## Top Verticals

1. **Financial Services** â€” High compliance burden, massive document processing, willingness to pay for automation. Regulated = sticky.
2. **Legal** â€” Document review, contract analysis, due diligence. Time = money here more than anywhere.
3. **Healthcare** â€” Administrative burden is crushing. Regulatory complexity creates barriers to entry for competitors.

### Why These Three

All share: high cost of human labor, heavy regulatory overhead, document-intensive workflows, and willingness to pay premium for reliability. The compliance moat protects us once we're in.

## Competitive Landscape

- Big consultancies (Accenture, Deloitte) â€” slow, expensive, not AI-native
- Pure AI startups â€” fast but lack enterprise trust and delivery capability
- Hyperscalers (Azure AI, AWS) â€” platform tools, not solutions. Customers still need someone to implement.
- **Our edge:** We sit between consultancy trust and startup speed. African talent arbitrage gives margin advantage.

## Pricing Model

- ~32 customers Ã— ~$344K ACV = $11M ARR
- Value-based pricing anchored to **recovered capacity** (FTE equivalents saved)
- NOT selling "AI agents" â€” selling hours back, risk reduced, throughput increased

## Key Strategic Insight

> **"Sell recovered capacity, not AI agents."**

Customers don't buy technology. They buy outcomes. Frame everything as: "We give you back X hours/week of senior staff time" or "We reduce your processing time from Y days to Z hours." The AI is the how, not the what.

## US Market Entry

- **Delaware LLC** â€” Standard structure for UK company entering US
- **SOC 2 Type II** â€” Non-negotiable for enterprise sales in financial services and healthcare
- Target: East Coast initially (NYC financial services, Boston healthcare)
- Need US-based sales presence within 6 months of first US customer

## Key Intelligence (Updated 2026-02-13)

- **Lyzr.ai** raised $10.5M with Accenture as investor, created "Agentic Transformation Consultants" â€” direct competitor signal. Generalist approach is their weakness vs. our vertical focus.
- **Insurance** emerging as strong sub-vertical under Financial Services. Giants deploying agentic AI in back offices (PYMNTS, Feb 12). Same buyer profile as banking.
- **Microsoft** actively pushing healthcare agentic AI readiness â€” doing our market education for free. Position as implementation layer on top of Azure.
- **AI funding** remains massive ($55B+ Jan 2026). Investors want revenue traction, not prototypes. Our VADIS pre-payment is strong signal.
- **Thomson Reuters 2026 Report**: 40% org-wide AI adoption in professional services, only 18% track ROI. Our "recovered capacity" framing directly solves this gap.

## Key Intelligence (Updated 2026-02-14)

- **AI Scare Trade (Feb 14):** Anthropic legal AI plug-in triggered market-wide selloff. S&P Software lost ~$2T from peak. Brokerages, legal services, data analytics all hit. This creates URGENCY for our buyers â€” fear of disruption = budget allocation for AI transformation.
- **Anthropic entering legal vertical directly** â€” elevated to ðŸ”´ High threat on competitive tracker. Monitor weekly. Our moat remains implementation + domain expertise, not the model.
- **Agentic AI vs RPA narrative now mainstream** â€” industry validating that agents automate decisions, not just tasks. Supports "recovered capacity" pricing.
- **Riff white paper** validates our Step 1â†’2 thesis: domain expertise encoded into working software is the unlock.

## Key Intelligence (Updated 2026-02-16)

- **GC Client Revolt:** General Counsel publicly stating law firms deliver zero AI benefit to clients despite internal adoption. Room of 500+ GCs agreed. This is the strongest organic demand signal for our legal vertical â€” buyers are frustrated and looking for alternatives. "Bypass the law firm AI tax" is our messaging wedge.
- **Harvey AI Dallas expansion (April 2026):** 6-week clock. They're moving from SF into enterprise territory. Dallas/Houston corridor = legal + insurance + energy. We must be in market before they establish local presence.
- **Microsoft Copilot Studio enterprise push:** Accelerates commoditization of agent platform layer. Validates our Step 2 timing â€” platform is free, implementation is the product.
- **Healthcare prior auth + legal revolt = two forced-buyer markets in 2026.** Sequence: legal first (VADIS proof), healthcare second (CMS mandate pressure Q3-Q4).
- **Contrarian flag logged:** Legal may be too crowded (Harvey, Anthropic, Thomson Reuters). Healthcare prior auth has fewer competitors + regulatory forcing function. Decision gate: track conversion rate from first 10 legal conversations.

## Key Intelligence (Updated 2026-02-18)

- **Harvey AI at 25K workflows + celebrity brand deal** (Gabriel Macht from Suits). Clear mid-market push beyond BigLaw. Dallas expansion April 2026 still on track. Threat level remains ðŸ”´ High.
- **McKinsey stat: 25% enterprise workflows automated by agentic AI by 2028.** Use in every sales conversation as urgency anchor.
- **Legacy RPA (Blue Prism) rebranding as "agentic"** â€” reduces our education burden but increases noise. Vertical specificity is our differentiation.
- **New opportunity identified: Corporate legal departments (in-house)** as distinct from law firms. Harvey serves supply side (firms), we can own demand side (corporate legal ops). GC revolt + Harvey's market education = warm buyers looking for alternatives.

## Open Strategic Questions

- When do we move from Step 1 (Skills) to Step 2 (Service Accounts)?
- Which vertical do we lead with for US entry? (Legal is consensus, but healthcare contrarian case is strong)
- Partnership vs direct sales for initial US traction?
- How do we price the transition from project-based to AaaS?
- Should we target Dallas/Houston as first US geography given Harvey's move there?
- Decision gate: If legal outbound converts <15% after 10 conversations, pivot healthcare to lead?
- Is our demand-side legal differentiation structural or merely temporal? (Contrarian flag 2026-02-18)
- First 5 legal discovery calls should probe Harvey evaluation experience specifically

## TARGET MARKET
- **US ONLY** â€” AfrexAI is a US-based company
- Focus on US competitive landscape and US market opportunities
- Currency: USD ($)

## Shared Reference
- **ALWAYS read**: /Users/openclaw/.openclaw/workspace-main/agents/SHARED-CONTEXT.md for CRM schema, Stripe data, Gmail access, and key links.
